OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 81.5% in January

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 289,406 shares, an increase of 81.5% from the January 15th total of 159,454 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 373,038 shares, the short-interest ratio is presently 0.8 days. Based on an average daily trading volume, of 373,038 shares, the short-interest ratio is presently 0.8 days. Currently, 1.3% of the shares of the stock are short sold.

Hedge Funds Weigh In On OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Citadel Advisors LLC purchased a new stake in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 15,355 shares of the company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 2.97% of the company’s stock.

OKYO Pharma Stock Performance

OKYO Pharma stock traded down $0.42 during midday trading on Friday, reaching $1.75. The company’s stock had a trading volume of 2,085,044 shares, compared to its average volume of 277,893. OKYO Pharma has a 52 week low of $1.03 and a 52 week high of $3.35. The business has a 50-day moving average price of $2.14 and a 200-day moving average price of $2.26.

OKYO Pharma (NASDAQ:OKYO) last announced its quarterly earnings results on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($2.21). As a group, analysts expect that OKYO Pharma will post -0.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OKYO has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a research report on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, January 22nd. Finally, B. Riley Financial assumed coverage on shares of OKYO Pharma in a report on Monday, December 8th. They issued a “buy” rating and a $5.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, OKYO Pharma presently has a consensus rating of “Hold” and an average price target of $6.00.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.